Fundz

Compugen Inc. strengthens Defence + Security Industry with Strategic Acquisition of SynerSolutions Technologies Inc.

PUBLIC · CGENNov 04, 2024

Acquiring Company

Compugen

Acquired Company

SynerSolutions Technologies

Tel AvivPhilippinesOtherBiotechnologyHealth CareMedicalTherapeuticsBiotechnology ResearchInformation TechnologyCyber SecurityNetwork Security

Description

Compugen Inc., the nation's largest privately-owned and operated Technology Ally, has proudly announced the acquisition of SynerSolutions Technologies Inc. This strategic acquisition underscores Compugen's commitment to delivering industry-leading, human-centric solutions, and enhances its security capabilities in the defence and security sectors. The combined strengths of Compugen and SynerSolutions will ensure that clients receive specialized support and achieve extraordinary results.

Who to call at Compugen, and when

When Compugen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.

  • An alert the day Compugen raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Compugen, from your own LinkedIn network
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Compugen

Location

26 HAROKMIM STREET

Tel Aviv, Tel Aviv District, Israel

About

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, is in IND enabling studies is licenced to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Compugen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Kara
Likely contact at this company
••••••••@••••••••

See Kara's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Compugen's next move

Learn about Strategic plan

Frequently asked

Who acquired SynerSolutions Technologies?

SynerSolutions Technologies was acquired by Compugen, based in Tel Aviv. The deal was reported on November 4, 2024. Compugen is publicly traded (CGEN) and operates in Other.

When did Compugen acquire SynerSolutions Technologies?

Compugen's acquisition of SynerSolutions Technologies was reported on November 4, 2024. Compugen Inc., the nation's largest privately-owned and operated Technology Ally, has proudly announced the acquisition of SynerSolutions Technologies Inc. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does SynerSolutions Technologies do?

SynerSolutions Technologies Inc. is an agile, focused, and resourceful cyber security firm that focuses on the intelligence and defence industries in support of the Government of Canada. It is privately held, operating in Information Technology, and is based in Philippines.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.